Memantine-associated reversal of clozapine-induced weight gain

被引：10
作者：
Schaefer, M.
Leopold, K.
Hinzpeter, A.
Heinz, A.
Krebs, M.
机构：
[1] Kliniken Essen Mitte, Dept Psychiat & Psychotherapy, D-45136 Essen, Germany
[2] Charite Univ Med Berlin, Dept Psychiat & Psychotherapy, Berlin, Germany
来源：
PHARMACOPSYCHIATRY | 2007年 / 40卷 / 04期
关键词：
D O I：
10.1055/s-2007-984391
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Weight gain is a frequently observed adverse event in the treatment with atypical antipsychotics that significantly affects the patients' physical health and treatment compliance. Methods: We report on a treatment-resistant schizophrenic patient who received an add-on treatment with the low-affinity NMDA antagonist memantine because of cognitive disturbances. Results: During this treatment we observed a marked decrease of clozapine-induced weight gain. The causal relationship to memantine could be demonstrated using an on-off-on design with a significant increase of weight after discontinuation and again a substantial weight loss after re-exposition with memantine. Beside weight, also negative symptoms improved. Discussion: Prospective controlled trials evaluating the safety and possible positive effects of memantine on antipsychotic induced weight gain are needed.
引用
收藏
页码：149 / 151
页数：3
相关论文
共 24 条
[1]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]   CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES [J].
ALVIR, JMJ ;
LIEBERMAN, JA ;
SAFFERMAN, AZ ;
SCHWIMMER, JL ;
SCHAAF, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :162-167
[3]   Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives [J].
Baptista, T ;
Kin, NMKNY ;
Beaulieu, S ;
de Baptista, EA .
PHARMACOPSYCHIATRY, 2002, 35 (06) :205-219
[4]   Management of treatment resistance in schizophrenia [J].
Conley, RR ;
Kelly, DL .
BIOLOGICAL PSYCHIATRY, 2001, 50 (11) :898-911
[5]   ANTIPSYCHOTIC AGENTS ANTAGONIZE NONCOMPETITIVE N-METHYL-D-ASPARTATE ANTAGONIST-INDUCED BEHAVIORS [J].
CORBETT, R ;
CAMACHO, F ;
WOODS, AT ;
KERMAN, LL ;
FISHKIN, RJ ;
BROOKS, K ;
DUNN, RW .
PSYCHOPHARMACOLOGY, 1995, 120 (01) :67-74
[6]   Amantadine for weight gain associated with olanzapine treatment [J].
Deberdt, W ;
Winokur, A ;
Cavazzoni, PA ;
Trzaskoma, QN ;
Carlson, CD ;
Bymaster, FP ;
Wiener, K ;
Floris, M ;
Breier, A .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (01) :13-21
[7]   Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function [J].
Duncan, GE ;
Moy, SS ;
Lieberman, JA ;
Koller, BH .
PSYCHOPHARMACOLOGY, 2006, 184 (02) :190-200
[8]   MEMANTINE IS HIGHLY POTENT IN PROTECTING CORTICAL CULTURES AGAINST EXCITOTOXIC CELL-DEATH EVOKED BY GLUTAMATE AND N-METHYL-D-ASPARTATE [J].
ERDO, SL ;
SCHAFER, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 198 (2-3) :215-217
[9]   Schizophrenia [J].
Freedman, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18) :1738-1749
[10]   Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers [J].
Gouzoulis-Mayfrank, E ;
Heekeren, K ;
Neukirch, A ;
Stoll, M ;
Stock, C ;
Obradovic, M ;
Kovar, KA .
PHARMACOPSYCHIATRY, 2005, 38 (06) :301-311
123